S
Sabikun Nahar
Researcher at Harvard University
Publications - 18
Citations - 863
Sabikun Nahar is an academic researcher from Harvard University. The author has contributed to research in topics: Stromal cell & Bone marrow. The author has an hindex of 9, co-authored 13 publications receiving 773 citations.
Papers
More filters
Journal ArticleDOI
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
Gullu Gorgun,Elisabetta Calabrese,Teru Hideshima,Jeffrey Ecsedy,Giulia Perrone,Mala Mani,Hiroshi Ikeda,Giada Bianchi,Yiguo Hu,Diana Cirstea,Loredana Santo,Yu-Tzu Tai,Sabikun Nahar,Mei Zheng,Madhavi Bandi,Ruben D. Carrasco,Noopur Raje,Nikhil C. Munshi,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +20 more
TL;DR: The preclinical results suggest that MLN8237 may be a promising novel targeted therapy in MM, and combined with dexamethasone, doxorubicin, or bortezomib induces synergistic/additive anti-MM activity in vitro.
Journal ArticleDOI
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Gullu Gorgun,Elisabetta Calabrese,Ender Soydan,Teru Hideshima,Giulia Perrone,Madhavi Bandi,Diana Cirstea,Loredana Santo,Yiguo Hu,Yu-Tzu Tai,Sabikun Nahar,Naoya Mimura,Claire Fabre,Noopur Raje,Nikhil C. Munshi,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +17 more
TL;DR: It is demonstrated that modulation of SOCS1 may enhance immune response and efficacy of IMiDs in MM and the mechanism of inhibitory-cytokine signaling in effector cells and MM cells is defined.
Journal ArticleDOI
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
Ki Hyun Kim,Sun-Young Kong,Mariateresa Fulciniti,Xian-Feng Li,Weihua Song,Sabikun Nahar,Peter C. Burger,Mathew J. Rumizen,Klaus Podar,Dharminder Chauhan,Teru Hideshima,Nikhil C. Munshi,Paul G. Richardson,Ann M. Clark,Janet Ogden,Andreas Goutopoulos,Luca Rastelli,Kenneth C. Anderson,Yu-Tzu Tai +18 more
TL;DR: The results of this study support clinical evaluation of AS703026, alone or in combination with other anti‐MM agents, to improve patient outcome.
Journal ArticleDOI
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma
Jana Jakubikova,David Cervi,Melissa G. Ooi,Ki-Hyun Kim,Sabikun Nahar,Steffen Klippel,Dana Cholujova,Merav Leiba,John F. Daley,Jake Delmore,Joseph Negri,Simona Blotta,Douglas W. McMillin,Teru Hideshima,Paul G. Richardson,Jan Sedlak,Kenneth C. Anderson,Constantine S. Mitsiades +17 more
TL;DR: Sulforaphane and phenylethyl isothiocyanate enhanced the in vitro anti-myeloma activity of several conventional and novel therapies used in multiple myelomas and may enhance the activity of other anti-multiple myeloma agents.
Journal ArticleDOI
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
Yu-Tzu Tai,Ender Soydan,Weihua Song,Mariateresa Fulciniti,Ki Hyun Kim,Ki Hyun Kim,Fangxin Hong,Xian Feng Li,Peter C. Burger,Matthew Rumizen,Sabikun Nahar,Klaus Podar,Teru Hideshima,Nikhil C. Munshi,Giovanni Tonon,Ruben D. Carrasco,Ruben D. Carrasco,Daniel E. H. Afar,Kenneth C. Anderson +18 more
TL;DR: This article showed that CS1 knockdown using lentiviral short-interfering RNA decreased phosphorylation of ERK1/2, AKT, and STAT3 in multiple myeloma (MM) patients.